HomeCompareCTIHY vs JNJ

CTIHY vs JNJ: Dividend Comparison 2026

CTIHY yields 1.61% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $4.7K in total portfolio value· pulled ahead in Year 8
10 years
CTIHY
CTIHY
● Live price
1.61%
Share price
$69.18
Annual div
$1.11
5Y div CAGR
16.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$928.59
Full CTIHY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — CTIHY vs JNJ

📍 JNJ pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCTIHYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CTIHY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CTIHY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CTIHY
Annual income on $10K today (after 15% tax)
$136.95/yr
After 10yr DRIP, annual income (after tax)
$789.30/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,196.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CTIHY + JNJ for your $10,000?

CTIHY: 50%JNJ: 50%
100% JNJ50/50100% CTIHY
Portfolio after 10yr
$27.9K
Annual income
$2,809.00/yr
Blended yield
10.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

CTIHY
No analyst data
Altman Z
0.4
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CTIHY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCTIHYJNJ
Forward yield1.61%2.13%
Annual dividend / share$1.11$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR16.5%28%
Portfolio after 10y$25.5K$30.3K
Annual income after 10y$928.59$4,689.40
Total dividends collected$4.7K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CTIHY vs JNJ ($10,000, DRIP)

YearCTIHY PortfolioCTIHY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,888$187.71$10,592$272.30+$296.00CTIHY
2$11,872$222.51$11,289$357.73+$583.00CTIHY
3$12,968$264.18$12,123$472.89+$845.00CTIHY
4$14,190$314.17$13,141$629.86+$1.0KCTIHY
5$15,557$374.29$14,408$846.81+$1.1KCTIHY
6$17,093$446.80$16,021$1,151.60+$1.1KCTIHY
7$18,824$534.49$18,122$1,588.22+$702.00CTIHY
8← crossover$20,782$640.88$20,930$2,228.20$148.00JNJ
9$23,008$770.39$24,792$3,191.91$1.8KJNJ
10$25,547$928.59$30,274$4,689.40$4.7KJNJ

CTIHY vs JNJ: Complete Analysis 2026

CTIHYStock

China Taiping Insurance Holdings Company Limited, an investment holding company, underwrites various insurance and reinsurance products in the People's Republic of China and internationally. The company operates through three business segments: Life Insurance, Property and Casualty Insurance, and Reinsurance. The Life Insurance segment provides life insurance products, such as individual and group life insurance, health insurance, and accident insurance products and annuities. The Property and Casualty Insurance segment offers compulsory motor insurance, liability insurance, credit insurance, guarantee insurance, and short-term accident and health insurance, as well as the related reinsurance products. The Reinsurance segment provides property damage, life, marine cargo and hull, and miscellaneous non-marine reinsurance products. The company also engages in the assets management, insurance intermediary, financial leasing, property investment, and securities dealing and broking, as well as in elderly care investment businesses; and manages investment funds. In addition, it provides corporate and personal retirement insurance products; and back-to-back financing arrangement, as well as insurance broking and agency services. The company was formerly known as China Insurance International Holdings Company Limited and changed its name to China Taiping Insurance Holdings Company Limited in August 2009. The company was incorporated in 2000 and is headquartered in North Point, Hong Kong. China Taiping Insurance Holdings Company Limited is a subsidiary of China Taiping Insurance Group (HK) Company Limited.

Full CTIHY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this CTIHY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CTIHY vs SCHDCTIHY vs JEPICTIHY vs OCTIHY vs KOCTIHY vs MAINCTIHY vs ABBVCTIHY vs MRKCTIHY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.